University of Szeged
Szeged, 6725, Hungary
NCT Number: NCT07675369
The goal of this clinical trial is to learn if simple, easy-to-use educational materials can help people with inflammatory bowel disease (IBD) better understand their condition. The study will also look at how people feel about using these materials and if the education affects their daily life and well-being.
The main questions it aims to answer are:
* Does the education help people score higher on the IBD-KNOW questionnaire after three months * How satisfied are people with the written or audio materials * Does the education affect quality of life, mental health, or IBD disease activity
Researchers will compare written and audio education to see which format works better for learning and user experience.
Participants will:
* Fill out questionnaires at the start of the study and again after three months * Receive written or audio educational materials if they are in one of the education groups * Complete short surveys about quality of life, mental health, and IBD symptoms if they receive the educational materials
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Szeged, 6725, Hungary
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A structured written PDF booklet covering key domains of inflammatory bowel disease, including anatomy, physiology, etiology, risk factors, pathology, diagnosis, treatments and targets, monitoring, surgeries, pregnancy, and vaccines. The material is explicitly designed to address all questions related to the IBD-KNOW questionnaire, and was developed by expert gastroenterologists, ensuring comprehensive educational coverage.
A structured audio podcast covering key domains of inflammatory bowel disease, including anatomy, physiology, etiology, risk factors, pathology, diagnosis, treatments and targets, monitoring, surgeries, pregnancy, and vaccines. The material is explicitly designed to address all questions related to the IBD-KNOW questionnaire, and was developed by expert gastroenterologists, ensuring comprehensive educational coverage.
Time frame: Three months after enrollment (CONT group) or receiving the educational material (READ and HEAR groups).
Change in the scores of the 35-item extended Inflammatory Bowel Disease Knowledge (IBD-KNOW) questionnaire to assess knowledge retention and evaluate user experience.
The original IBD-KNOW questionnaire is a validated tool for measuring disease-related knowledge among patients with inflammatory bowel disease. It consists of 24 items covering anatomy and function, epidemiology, diet and lifestyle, general IBD knowledge, medications, complications, surgeries, pregnancy, and vaccinations.
For this study, 11 additional items (items 25-35) were developed by IBD expert gastroenterologists to assess knowledge related to treatment, monitoring, and follow-up strategies. All items use simple True / False / Do not know response options.
Total scores range from 0 to 35 points, with higher scores indicating better disease-related knowledge.
Time frame: Three months after receiving the educational material (READ and HEAR groups).
Participant satisfaction with the educational material is measured using a 0-10 Likert scale to provide standardized, objective assessment of user experience.
The scale ranges from 0 (not satisfied at all) to 10 (extremely satisfied), with higher scores indicating greater satisfaction with the educational content.
Time frame: Three months after receiving the educational material (READ and HEAR groups).
A follow-up questionnaire assessing patients' subjective experiences with telemedical education and its impact on quality of life using the Short Inflammatory Bowel Disease Questionnaire (SIBDQ).
The SIBDQ is a validated self-reported measure of health-related quality of life in IBD, consisting of 10 items, each rated on a 1-7 Likert scale.
Total scores range from 10 to 70, with higher scores indicating better health-related quality of life.
Time frame: Three months after receiving the educational material (READ and HEAR groups).
A follow-up questionnaire assessing patients' subjective experiences with telemedical education and its impact on mental health using the Patient Health Questionnaire-9 (PHQ-9).
The PHQ-9 is a validated, self-administered 9-item depression severity scale, with each item scored from 0 (not at all) to 3 (nearly every day). Total scores range from 0 to 27, with higher scores indicating more severe depressive symptoms.
An additional functional-impairment item asks how difficult the reported problems have made it for patients to work, manage household responsibilities, or interact with others.
Time frame: Three months after receiving the educational material (READ and HEAR groups).
A follow-up questionnaire assessing patients' subjective experiences with telemedical education and its impact on disease activity.
Participants rate agreement (Agree / Do not agree) with statements regarding lifestyle modification, disease management, frequency of flares and overall quality of life.
Szeged University
Other
Nationwide Survey of Telemedicinal Patient Education in IBD - Baseline Knowledge Gaps and a Randomized Comparison of Podcast Versus Written Format
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06773182
Behavior, Colitis
Hamilton, Ontario, Canada
View Trial DetailsNCT07699926
Colonic Diseases, Colonic Diseases, Functional
Cheras, Kuala Lumpur, Malaysia
View Trial DetailsNCT07660289
Combination Therapy, Combined Advanced Targeted Therapy
Xi'an, Shaanxi, China
View Trial DetailsNCT07616791
Digestive System Diseases, Gastroenteritis
Beijing, China
View Trial Details